Nektar Therapeutics (NASDAQ:NKTR) announced today that it has received a
"We're pleased that MOVANTIK is now available as an important treatment option for the millions of patients suffering from opioid-induced constipation," said
MOVANTIK was developed using
Shares of Nektar closed yesterday at $10.82 . NKTR has a 1-year high of $17.53 and a 1-year low of $10.10. The stock's 50-day moving average is $12.78 and it's 200-day moving average is $13.87.
On the ratings front, Nektar has been the subject of a number of recent research reports. In a report issued on March 18, Piper Jaffray analyst Joshua Schimmer maintained a Buy rating on NKTR, with a price target of $15, which implies an upside of 38.6% from current levels. Separately, on the same day, Jefferies Co.'s David Steinberg maintained a Buy rating on the stock and has a price target of $14.
According to TipRanks.com, which ranks over 7,500 financial analysts and bloggers to gage the performance of their past recommendations, Joshua Schimmer and David Steinberg have a total average return of 14.9% and 21.5% respectively. Schimmer has a success rate of 61.4% and is ranked #278 out of 3564 analysts, while Steinberg has a success rate of 75.9% and is ranked #364.
The street is mostly Bullish on NKTR stock. Out of 5 analysts who cover the stock, 5 suggest a Buy rating . The 12-month average price target assigned to the stock is $16.80, which implies an upside of 55.3% from current levels.
Nektar Therapeutics Inc is a clinical-stage biopharmaceutical company. The Company develops a pipeline of drug candidates that utilizes its PEGylation and polymer conjugate technology platforms that are designed to developmolecular entities.